<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646409</url>
  </required_header>
  <id_info>
    <org_study_id>thromboembolism and bleeding</org_study_id>
    <nct_id>NCT03646409</nct_id>
  </id_info>
  <brief_title>Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer</brief_title>
  <acronym>VENETIA</acronym>
  <official_title>Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding
      incidence from the start of cancer diagnosis in a retrospective cohort of patients with
      esophageal cancer. Additionally, the predictive value of the Khorana score and several other
      VTE and bleeding prediction scores and risk factors will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cancer are at high risk of venous thromboembolism (VTE), including deep-vein
      thrombosis and pulmonary embolism. For cancer patients receiving chemotherapy the incidence
      of VTE is even higher.

      Several predictive models were previously developed to identify and justify
      thromboprophylaxis for cancer patietns who are at highest risk of VTE, like the Khorana and
      PROTECHT score. The Khorana score is a risk-stratification tool to select patients at high
      risk of VTE for thromboprophylaxis. The PROTECHT score takes cisplatin-based chemotherapy
      into account in addition of the Khorana score.

      Thereby, the incidence of bleeding and VTE in patients with esophageal cancer is not clear.

      This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding
      incidence from the start of cancer diagnosis in a retrospective cohort of patients with
      esophageal cancer. Additionally, the predictive value of the Khorana score and several other
      VTE and bleeding prediction scores and risk factors will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VTE- and bleeding incidence</measure>
    <time_frame>from start of cancer diagnosis</time_frame>
    <description>6- and 12-month VTE- and bleeding incidence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive performance of VTE risk factors and known prediction models</measure>
    <time_frame>from start cancer diagnosis</time_frame>
    <description>To assess the predictive value of Khorana, modified Vienna-, and PROTECHT score in Predictive performance of VTE risk factors and known prediction models</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive performance of bleeding risk factors and known prediction models</measure>
    <time_frame>from start cancer diagnosis</time_frame>
    <description>Predictive performance of bleeding risk factors and known prediction models</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolism (ATE) incidence</measure>
    <time_frame>from start of cancer diagnosis</time_frame>
    <description>6- and 12-month ATE incidence</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">542</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Esophagus Cancer</condition>
  <condition>Bleeding</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Patients with esophageal cancer receiving chemotherapy</arm_group_label>
    <description>Patients &gt; 18 years with esophageal cancer receiving neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous thromboembolic event, arterial thromboembolic event, bleeding events</intervention_name>
    <description>Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy</description>
    <arm_group_label>Patients with esophageal cancer receiving chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with esophageal cancer, receiving chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Esophageal cancer patients

          -  Receiving chemotherapy

          -  Age at least 18 years old

        Exclusion Criteria:

        - Death &lt;3 months after cancer diagnosis (baseline)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry R Büller, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013 Sep 5;122(10):1712-23. doi: 10.1182/blood-2013-04-460121. Epub 2013 Aug 1. Review.</citation>
    <PMID>23908465</PMID>
  </reference>
  <reference>
    <citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007 Nov 15;110(10):2339-46.</citation>
    <PMID>17918266</PMID>
  </reference>
  <reference>
    <citation>Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2009 Aug 10;27(23):3786-93. doi: 10.1200/JCO.2008.19.4274. Epub 2009 Apr 27.</citation>
    <PMID>19398575</PMID>
  </reference>
  <reference>
    <citation>Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23.</citation>
    <PMID>18216292</PMID>
  </reference>
  <reference>
    <citation>Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013 Sep 19;122(12):2011-8. doi: 10.1182/blood-2013-04-460147. Epub 2013 Aug 1. Review.</citation>
    <PMID>23908470</PMID>
  </reference>
  <reference>
    <citation>Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012 Jun;7(3):291-2. doi: 10.1007/s11739-012-0784-y. Epub 2012 May 1.</citation>
    <PMID>22547369</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Harry R. Buller</investigator_full_name>
    <investigator_title>Prof. dr. H.R. Büller, principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

